Evidence map›Paper›PMID 37092563›Full record

ArticleCNS oncology2023

Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report.

Huda Alalami, Serguei Bannykh, Xuemo Fan, Jethro Hu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Huda AlalamiNeurology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0003-3434-9043
Serguei BannykhPathology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
Xuemo FanPathology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
Jethro HuNeurology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
Cedars-Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common malignant brain tumor. Less than 1% of patients survive longer than 10 years. A 77-year-old woman was diagnosed with MGMT-methylated GBM in 2009. The patient received cilengitide as part of the CENTRIC clinical trial in conjunction with standard radiation and chemotherapy. Though the study was halted in 2013, our patient received cilengitide until 2016 with no radiographic evidence of recurrence thus far. This is the oldest reported GBM patient with greater than 10-year survival. Her exceptional response may have been influenced by MGMT promoter methylation status and PTEN expression.

Indexed as

Brain NeoplasmsGlioblastomaChildDacarbazineDNA MethylationDNA Modification MethylasesDNA Repair EnzymesFemaleHumansPrognosisSnake VenomsTemozolomideCilengitideDacarbazineDNA Modification MethylasesDNA Repair EnzymesSnake VenomsTemozolomidebiomarkercilengitideglioblastomaintegrinstreatment

Identifiers

PMID37092563
PMCPMC10171035
OpenAlexW4366821914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.